alexa Fluvastatin Increases AQP2 Urine Excretion in a Dyslipidemic Patient with Nephrogenic Diabetes Insipidus: An In Vivo and In Vitro Study | OMICS International | Abstract
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Fluvastatin Increases AQP2 Urine Excretion in a Dyslipidemic Patient with Nephrogenic Diabetes Insipidus: An In Vivo and In Vitro Study

Giuseppe Procino1*, Maiolo D2, Barbieri C1, Milano S1, Carmosino M1, Squatrito S2, Svelto M1,3 and Gullo D2

1Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Italy

2Endocrinology Unit, Garibaldi-Nesima Hospital, University of Catania Medical School, Catania, Italy

3The National Research Council (CNR), Bari, Italy

*Corresponding Author:
Giuseppe Procino
Department of Biosciences
Biotechnologies and Biopharmaceutics
Via Amendola 165/A 70126, Bari, Italy
Tel: +39 0805443414
Fax: +39 0800000000
E-mail: [email protected]

Received date: June 05, 2014; Accepted date: July 26, 2014; Published date: August 03, 2014

Citation: Procino G, Maiolo D, Barbieri C, Milano S, Carmosino M, et al. (2014) Fluvastatin Increases AQP2 Urine Excretion in a Dyslipidemic Patient with Nephrogenic Diabetes Insipidus: An In Vivo and In Vitro Study. J Diabetes Metab 5:408 doi: 10.4172/2155-6156.1000408

Copyright: © 2014 Procino G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Objective: Among the pleiotropic effects of statins, we have previously reported that fluvastatin increases the amount of plasma membrane-expressed AQP2 in renal collecting duct cells both in vitro and in vivo, independently of vasopressin. This effect may be of potential clinical significance for the treatment of patients affected by nephrogenic diabetes insipidus forms caused by inactivating mutations of the vasopressin type 2 receptor. Here we report the effect of fluvastatin on AQP2 plasma membrane abundance on an adult male XNDI patient treated with statins.

Methods: An adult male NDI patient, carrying an inactivating mutation of the V2R, under conventional treatment to reduce polyuria, was also treated with fluvastatin because of high levels of blood cholesterol. AQP2 plasma membrane expression in the kidney was monitored by measuring urinary excreted AQP2 (u-AQP2), before starting fluvastatin treatment and during a three months follow-up period. The effect of fluvastatin was also tested in vitro in mouse kidney cortical collecting duct MCD4 cells.

Results: u-AQP2 increased in a time- and dose-dependent manner after treatment with 40 and 80 mg/day of fluvastatin for 90 days. However, at this drug dosage, increased uAQP2 was not accompanied by reduction of diuresis and increase of urine osmolality. The effect of fluvastatin on AQP2 excretion was confirmed in vitro in cultured renal cells.

Conclusions: We first demonstrate that the use of fluvastatin increased AQP2 plasma membrane expression in an NDI dyslipidemic patient. This observation was confirmed by in vitro studies using mouse cultured renal cells treated with fluvastatin. Although a clinical relevant effect of fluvastatin on total diuresis and urine osmolality was not observed at the used dosages, these results suggest further investigation on the possible role of HMG CoA reductase inhibitors to improve the efficacy of the current NDI therapy.

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7